• Pediatric Solid Tumor Clinical Trials

    Many of the biggest breakthroughs in the way pediatric blood disorders and cancers are treated can be traced back to research performed at Dana-Farber Cancer Institute and Boston Children’s Hospital. We published the first experience with double autologous peripheral blood stem cell transplant for high-risk neuroblastoma. We are a leader in clinical trials for Ewing sarcoma; five-year event-free survival rates are now at about 70 percent. Today, we are pioneering the use of interventional radiology for the surgical removal of pediatric tumors, and we are one of only a few centers nationally to offer I-131 MIBG therapy for children with relapsed neuroblastoma. Continue reading to learn about our current clinical trials for children with solid tumors.

    Questions? Contact Us.

    If you need help determining whether your child might be eligible for one of our clinical trials, email us at clinicaltrials@danafarberbostonchildrens.org. We can help you navigate your options. Or read our clinical trial FAQ for answers to general questions.

    Search for Trials by Condition

    Search for clinical trials by condition using the links below, or download a summary of all current trials at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

  • Contact Us

    Call 1-855-320-2092. We can answer questions about treatment or new patient scheduling.
  • Solid Tumor Clinical Trials

    Through research and clinical trials, we are developing innovative therapies and helping to improve treatment for solid tumors.callout bg
  • Clinical Trials for Relapsed Cancer

    acct programFor patients with relapsed, refractory, or recurrent cancer, early phase clinical trials may be a treatment option.
  • Our Affiliations

    HMS Callout FAD 

    Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.